Christine L Kempton

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint How we treat a hemophilia A patient with a factor VIII inhibitor
    Christine L Kempton
    Aflac Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Blood 113:11-7. 2009
  2. ncbi request reprint Inhibitors in previously treated patients: a review of the literature
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service and Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Haemophilia 16:61-5. 2010
  3. pmc In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service and Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
    J Thromb Haemost 8:2224-31. 2010
  4. pmc Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A
    Christine L Kempton
    Emory University, Atlanta, Georgia 30322, USA
    Am J Hematol 87:933-6. 2012
  5. ncbi request reprint Toward optimal therapy for inhibitors in hemophilia
    Christine L Kempton
    AFLAC Cancer and Blood Disorders Center, Children s Healthcare of Atlanta, and Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
    Blood 124:3365-72. 2014
  6. pmc Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein
    Ryan J Summers
    Emory University School of Medicine, Atlanta, GA, USA
    Blood 117:3190-8. 2011

Collaborators

Detail Information

Publications6

  1. ncbi request reprint How we treat a hemophilia A patient with a factor VIII inhibitor
    Christine L Kempton
    Aflac Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Blood 113:11-7. 2009
    ..Ideally, prediction and ultimately prevention will come with an improved understanding of how patient-specific and treatment-related factors work together to influence anti-factor VIII antibody production...
  2. ncbi request reprint Inhibitors in previously treated patients: a review of the literature
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service and Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Haemophilia 16:61-5. 2010
    ..This review will discuss the published literature on epidemiology and clinical characteristics of inhibitors and possible risk factors for formation in PTPs...
  3. pmc In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service and Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
    J Thromb Haemost 8:2224-31. 2010
    ..Although intensive FVIII treatment has long been considered a risk factor for inhibitor development in those with non-severe disease, its strength of association and the influence of other factors have remained undefined...
  4. pmc Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A
    Christine L Kempton
    Emory University, Atlanta, Georgia 30322, USA
    Am J Hematol 87:933-6. 2012
    ..4 (95% CI = 1.06–20.03) and 10.21 (95% CI = 1.17–78.28), respectively], whereas ITI alone (n = 9) was not [HR = 1.35 (95% CI = 0.44–4.07)]...
  5. ncbi request reprint Toward optimal therapy for inhibitors in hemophilia
    Christine L Kempton
    AFLAC Cancer and Blood Disorders Center, Children s Healthcare of Atlanta, and Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
    Blood 124:3365-72. 2014
    ..However, for the group of patients who fail to respond to ITI or have hemophilia B, new and improved tools are needed. ..
  6. pmc Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein
    Ryan J Summers
    Emory University School of Medicine, Atlanta, GA, USA
    Blood 117:3190-8. 2011
    ....